(NASDAQ: KTRA) Kintara Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Kintara Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast KTRA's revenue for 2025 to be $1,357,175,203, with the lowest KTRA revenue forecast at $1,357,175,203, and the highest KTRA revenue forecast at $1,357,175,203. On average, 1 Wall Street analysts forecast KTRA's revenue for 2026 to be $5,484,005,425, with the lowest KTRA revenue forecast at $5,484,005,425, and the highest KTRA revenue forecast at $5,484,005,425.
In 2027, KTRA is forecast to generate $9,692,686,474 in revenue, with the lowest revenue forecast at $9,692,686,474 and the highest revenue forecast at $9,692,686,474.